Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim in Severe Bullous Drug Eruptions (SJS/TEN)
2024-515275-35-00Phase 3Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Aug 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of filgrastim in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Proportion of patients with halt in progression of skin detachment at Day 5. Planned start Aug 2024; status: authorised.
02
Drugs
filgrastim
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on 2024-515275-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515275-35-00.